Oncology · Surgery · 2 h ago
Machine perfusion and HCC recurrence after liver transplantation
A retrospective analysis of the UNOS database compared post-transplant outcomes among patients with hepatocellular carcinoma (HCC) whose donor livers did or did not undergo machine perfusion. Overall, machine perfusion was not associated with recurrence or survival; a subgroup beyond Milan criteria showed lower early recurrence, a finding the authors say needs validation.
- No recurrence difference in the overall matched population
- Lower one- and three-year recurrence in a subgroup beyond Milan criteria
- Overall survival did not differ significantly
- Small subgroup and event counts limit interpretation
Researchers used the United Network for Organ Sharing database to retrospectively assess whether machine perfusion of donor livers was associated with HCC recurrence or overall survival after liver transplantation in recipients with a pre-transplant HCC diagnosis. They matched groups 1:1 on baseline characteristics using propensity scores. The source does not report the sample size or effect estimates.
In the overall population, machine perfusion was not associated with HCC recurrence at one or three years. Among recipients whose tumor burden at listing was beyond Milan criteria, machine perfusion was associated with a reduced risk of recurrence at both time points. One- and three-year post-transplant overall survival did not differ significantly between groups.
The authors describe the subgroup finding as potentially indicating reduced early recurrence, but note that the subgroup and event counts were small. The retrospective database analysis is also subject to limitations in the data captured. The findings do not establish a survival benefit, and the authors call for validation in larger, potentially prospective cohorts.
In practice
For patients with HCC undergoing liver transplantation, this retrospective UNOS analysis found no association between donor-liver machine perfusion and recurrence in the overall matched population, or with one- or three-year overall survival. A subgroup with tumor burden beyond Milan criteria at listing had lower recurrence at one and three years with machine perfusion. This subgroup result is preliminary: the subgroup and event counts were small, the study was retrospective, and the authors call for larger, potentially prospective validation. It does not establish a survival benefit or justify changing practice on its own.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Annals of Surgical Oncology: ASO Author Reflections: Machine Perfusion Use and Liver Transplantation for Hepatocellular Carcinoma ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.